stockrow
Saturday 7 November 2026
Export IVA’s income statement to Excel — free account
Inventiva S.A. Sponsored ADR
Inventiva S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, down 43.7% from fiscal 2024.
3.77
0.14
+3.86%
Follow IVA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 10 | 6 | 4 | 13 | 6 | 10 | 20 | 25 | 16 | 9 | 20 | (1.1%) | 6 | 2 | 141 | +150.3% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | +100.0 pt | ||||||
| EBT | (18) | (32) | (44) | (34) | (38) | (58) | (57) | (119) | (199) | (401) | (160) | +41.5% | ||||||
| EBT margin, % | (176.94) | (556.22) | (1,194.90) | (267.63) | (638.78) | (579.59) | (288.58) | (474.11) | (1,248.89) | (4,467.77) | (814.74) | (4,290.8) pt | ||||||
| Net income | (7) | 0 | (39) | (34) | (38) | (59) | (57) | (120) | (199) | (401) | (280) | +55.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.63 | 0.37 | 0.18 | 0.54 | 0.18 | 0.26 | 0.48 | 0.55 | 0.27 | 0.05 | 0.00 | (24.9%) | |||||
| Earnings | (0.47) | (1.48) | (1.89) | (1.43) | (1.13) | (1.50) | (1.38) | (2.63) | (3.33) | (2.15) | (3.56) | +18.3% | ||||||
| Cash flow | (1.00) | (1.32) | (1.91) | (1.35) | (1.03) | (1.44) | (1.14) | (1.95) | (1.56) | (0.64) | 0.00 | (4.9%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (1.00) | (1.32) | (1.91) | (1.36) | (1.04) | (1.45) | (1.16) | (1.96) | (1.56) | (0.64) | 0.00 | (4.9%) | ||||||
| Book value | 2.40 | 4.81 | 3.45 | 1.97 | 3.75 | 2.68 | 1.16 | (0.76) | (1.93) | (0.17) | 0.00 | n/m | ||||||
| Shares, m | 16 | 16 | 21 | 24 | 34 | 39 | 41 | 45 | 60 | 187 | 51 | +31.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.00 | 44.07 | 44.07 | 44.07 | 70.80 | 70.85 | 9.67 | 9.24 | 4.22 | 9.16 | 7.43 | 30.6 | ||||||
| P/B | 8.56 | 8.56 | 8.56 | 8.56 | 4.09 | 5.28 | 4.00 | 0.00 | 0.00 | 0.00 | 2.13 | 4.8 | ||||||
| EV/Sales | 38.86 | 38.86 | 38.86 | 38.86 | 55.75 | 59.20 | 6.88 | 9.46 | 6.54 | 5.41 | 1.54 | 29.9 | ||||||
| EV/FCF | (5.44) | (5.44) | (5.44) | (5.44) | (6.02) | (5.23) | (1.46) | (1.44) | (1.22) | (0.77) | (0.22) | (3.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (16) | (20) | (39) | (32) | (35) | (56) | (47) | (88) | (93) | (119) | (137) | +25.3% | |||||
| Capex | 0 | (1) | (1) | 0 | 0 | (1) | (1) | 0 | 0 | 0 | (1) | +1.7% | ||||||
| Free cash flow | (16) | (20) | (39) | (32) | (35) | (57) | (48) | (89) | (93) | (119) | (138) | +25.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 34 | 70 | 65 | 39 | 136 | 110 | 80 | (2) | (10) | 189 | 211 | +20.9% | |||||
| Net debt | (26) | (71) | (65) | (40) | (109) | (90) | (55) | 11 | (46) | (45) | (116) | +6.4% | ||||||
| Shareholders’ equity | 38 | 75 | 71 | 46 | 127 | 105 | 48 | (35) | (115) | (32) | 69 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (10.52) | (89.41) | (53.98) | (43.52) | (34.52) | (38.76) | (42.91) | (121.02) | (195.41) | (194.96) | 0.00 | (184.4) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | (334.31) | (119.22) | (262.00) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (13.22) | (40.99) | (53.16) | (57.77) | (44.29) | (50.59) | (74.72) | (1,804.49) | 265.66 | 542.65 | 0.00 | +555.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 88 | 94 | 105 | 113 | 123 | 118 | 77 | — | (2.2%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.14 | 0.06 | 0.10 | 0.18 | 0.20 | 0.14 | 0.12 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2021 · fundamentals updated 26 Oct 2026
Inventiva S.A. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CTY City Therapeutics, Inc | $882.9M | — | — | — | — | — | — | — | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $880.0M | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $874.5M | — (loss-making) | — (loss-making) | +325.80% (above 0%: growing) | n/m | −142.63% (below 0%: shrinking) | 100.00% | (3.57%) | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $870.6M | 34.2× | — (loss-making) | +20.86% (above 0%: growing) | +190.91% (above 0%: growing) | +0.42% (above 0%: growing) | 86.90% | 25.34% | Compare |
| IVA Inventiva S.A. Sponsored ADR | $867.9M | — (loss-making) | — (loss-making) | −10.77% (below 0%: shrinking) | n/m | −20,989.22% (below 0%: shrinking) | 0.00% | 0.00% | |
| LTGO Latigo Biotherapeutics Inc | $862.6M | — | — | — | n/m | — | — | 0.00% | Compare |
| ANRO Alto Neuroscience, Inc. | $858.2M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| RIGL Rigel Pharmaceuticals, Inc. | $853.9M | 2.4× | 16.4× | +16.45% (above 0%: growing) | −54.84% (below 0%: shrinking) | +43.90% (above 0%: growing) | 86.67% | 21.15% | Compare |
| SNDX Syndax Pharmaceuticals, Inc. | $843.6M | — (loss-making) | — (loss-making) | +81.59% (above 0%: growing) | n/m | +61.43% (above 0%: growing) | 83.20% | (50.30%) | Compare |
| Median of peers | $866.6M | — | — | +51.23% | — | −1.50% | 86.67% | 0.00% |